The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD

Chest
R Grossman

Abstract

COPD is the fifth leading cause of death in the United States, and acute respiratory infections account for a significant proportion of all primary care visits. Approximately one half of all exacerbations of COPD can be attributed to bacterial infection, and antibiotic therapy has been demonstrated to improve clinical outcomes and hasten clinical and physiologic recovery. The major pathogen continues to be Haemophilus influenzae, and resistance to beta-lactam antibiotics such as ampicillin can be expected in 20 to 40% of isolated strains. Certain high-risk patients, in whom the cost of clinical treatment failure is high, can be identified by simple clinical criteria. Patients with significant cardiopulmonary comorbidity, frequent purulent exacerbations of COPD, advanced age, generalized debility, malnutrition, chronic corticosteroid administration, long duration of COPD, and severe underlying lung function tend to fail therapy with older drugs, such as ampicillin, and early relapse can be expected. Treatment directed toward resistant pathogens with potent bactericidal drugs may be expected to lead to improved clinical outcomes and overall lower costs, particularly if hospital admissions and respiratory failure can be prevented....Continue Reading

References

Mar 13, 1975·The New England Journal of Medicine·I Tager, F E Speizer
Jun 25, 1977·British Medical Journal·C Fletcher, R Peto
May 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H Jorgensen
Feb 15, 1990·The New England Journal of Medicine·R G Douglas
Nov 24, 1989·JAMA : the Journal of the American Medical Association·J M Eisenberg
Sep 1, 1989·Chest·A J Woolcock
Feb 1, 1988·The American Review of Respiratory Disease·D W DockeryA Spiro
Oct 16, 1965·British Medical Journal·P C ElmesT S Wilson
Oct 25, 1969·British Medical Journal·M FisherJ W Crofton
May 22, 1971·British Medical Journal·D C Morrell
Oct 1, 1983·Annals of Internal Medicine·D M MusherR E Baughn
Feb 1, 1982·The Journal of Infectious Diseases·R S IrwinJ T Kaemmerlen
Aug 1, 1995·Chest·R Wilson
Jan 1, 1994·Scandinavian Journal of Infectious Diseases·A Ortqvist
Sep 22, 1994·The New England Journal of Medicine·K L NicholT Von Sternberg
Oct 20, 1993·JAMA : the Journal of the American Medical Association·J C ButlerR R Facklam
Jun 2, 1993·JAMA : the Journal of the American Medical Association·M W HigginsM Lyles
Mar 28, 1996·The New England Journal of Medicine·M A Testa, D C Simonson
Feb 1, 1996·The Journal of Antimicrobial Chemotherapy·R WilsonP Ball
Aug 1, 1996·The European Respiratory Journal·J Dorca, A Torres
Aug 1, 1996·The European Respiratory Journal·G J HuchonM Woodhead
Dec 10, 1991·PharmacoEconomics·D A Freund, R S Dittus
Nov 30, 1957·British Medical Journal·P C ELMESA A DUTTON
Oct 1, 1962·British Journal of Diseases of the Chest·E C FEAR, G EDWARDS

❮ Previous
Next ❯

Citations

Jan 25, 2003·Surgical Infections·Joseph A PaladinoJerome J Schentag
May 17, 2000·Current Opinion in Pulmonary Medicine·S A Strassels
Mar 31, 2000·Current Opinion in Pulmonary Medicine·A Fein, A M Fein
Oct 13, 2006·Current Opinion in Infectious Diseases·D Banerjee, D Honeybourne
Feb 24, 2001·Clinics in Chest Medicine·P A Sherk, R F Grossman
Sep 11, 2004·Critical Care Nursing Clinics of North America·Rebecca Haynes Hockman
Aug 26, 1998·Lancet·J M Madison, R S Irwin
Feb 24, 2001·Clinics in Chest Medicine·G T Ferguson
Oct 15, 2013·British Journal of Nursing : BJN·Ann-Marie Aziz
May 11, 2001·The Annals of Pharmacotherapy·R L Russo, M D'Aprile
Jun 10, 2003·Emergency Medicine Clinics of North America·Kenneth H Palm, Wyatt W Decker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.